United States - English - NLM (National Library of Medicine)

hanul trading co., ltd. - levomenthol (unii: bz1r15mtk7) (levomenthol - unii:bz1r15mtk7), camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et), diphenhydramine (unii: 8gts82s83m) (diphenhydramine - unii:8gts82s83m), .alpha.-tocopherol, dl- (unii: 7qwa1rio01) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz), peppermint oil (unii: av092ku4jh) (peppermint - unii:v95r5kmy2b), nonivamide (unii: s846b891or) (nonivamide - unii:s846b891or) - levomenthol 2.769 mg in 0.2832 g - [purpose] topical analgesic [indications] anti-inflammatory effect to following symptoms: bruise, wrick, muscle pain, arthralgia, backache, shoulder pain, neuralgia, and rheumatic pain.

United States - English - NLM (National Library of Medicine)

zoetis inc. - tulathromycin (unii: q839i13422) (tulathromycin - unii:q839i13422), ketoprofen (unii: 90y4qc304k) (ketoprofen - unii:90y4qc304k) - draxxin® kp is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica , pasteurella multocida , histophilus somni , and mycoplasma bovis , and control of pyrexia associated with brd in beef steers, beef heifers, beef calves 2 months of age and older, beef bulls, dairy bulls, and replacement dairy heifers. not for use in reproducing animals over one year of age, dairy calves, or veal calves. the use of draxxin kp injection is contraindicated in animals previously found to be hypersensitive to tulathromycin and ketoprofen. not for human use. keep out of reach of children. the safety data sheet (sds) provides more detailed occupational safety information. to obtain a safety data sheet contact zoetis inc. at 1-888-963-8471.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

hankook korus pharm co. - paracetamol, pseudoephedrine (pseudoephedrine hydrochloride), chlorphenamine (chlorphenamine maleate) - tablets film-coated - 500mg+ 30mg+ 2mg (20/2x10/) and (100/10x10/) in blister

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); dorzolamide hydrochloride, quantity: 22.26 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops, solution - excipient ingredients: sodium hydroxide; benzalkonium chloride; hyetellose; water for injections; mannitol; sodium citrate dihydrate - the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 36mg;  ;   - transdermal patch - 17.4 mg/24h - active: rivastigmine 36mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 20 cm square release liner 40.5 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - etoposide - concentrate for solution for infusion - 20 milligram(s)/millilitre - podophyllotoxin derivatives; etoposide

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - irinotecan hydrochloride trihydrate - solution for infusion - 20 micromol - irinotecan

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis consumer health uk limited - nicotine - transdermal patch - 14 mg/24 hours

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - caspofungin acetate, quantity: 77.7 mg (equivalent: caspofungin, qty mg) - injection, powder for - excipient ingredients: mannitol; sucrose; sodium hydroxide; hydrochloric acid - caspofungin kp is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - caspofungin acetate, quantity: 55.5 mg (equivalent: caspofungin, qty 50 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; sucrose; hydrochloric acid - caspofungin kp is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.